MOTS-c

What it is

MOTS-c is a mitochondrial-derived peptide studied in metabolism and exercise biology. The online version of the story often compresses two very different facts: researchers can measure naturally occurring MOTS-c in people, and researchers can administer synthetic MOTS-c as a treatment. Evidence for the first does not prove the second.

What humans actually show

• Human exercise biology: A 2021 study randomized 30 healthy men to different exercise conditions and measured circulating and skeletal-muscle mitochondrial-derived peptides. It reported exercise-associated changes in endogenous MOTS-c. Participants were not treated with MOTS-c.
• Recent mechanistic work: A 2026 study primarily administered MOTS-c in two transgenic mouse strains and reported changes in skeletal-muscle mitochondrial bioenergetics. A separate human arm included seven healthy men performing one-legged exercise and measured endogenous MOTS-c; it did not administer MOTS-c to people or establish a clinical benefit.
• Human treatment evidence: FDA says the nomination did not include, and its search did not identify, clinical studies or human exposure data through any route. FDA separately states it did not identify studies evaluating administration of MOTS-c to humans.

The evidence supports calling MOTS-c an active research topic. It does not support clinical claims about injections improving weight, energy, muscle, or longevity.

FDA and U.S. status

FDA evaluated MOTS-c free base and MOTS-c acetate. Staff concluded the criteria weigh against placing either substance on the 503A Bulks List. The review emphasizes the absence of human administration data, incomplete safety information, characterization issues, and potential peptide aggregation and immunogenicity concerns.

On July 23, 2026, PCAC voted 7 yes, 5 no, 2 abstain on the free base and 7 yes, 5 no, 2 abstain on the acetate, recommending inclusion for both forms. The committee's recommendation is advisory: it does not approve MOTS-c, authorize a specific product, or itself place either form on the 503A Bulks List. FDA's final determination remains pending.

Risks and warning limits

FDA says potential human safety risks are unknown because it found no clinical studies or human exposure data. A peptide can be naturally present in the body and still have different effects when manufactured, formulated, and administered at an external concentration or route.

PepCurrent does not provide dosing, sourcing, or product-selection advice.

What would change this answer

• FDA's written meeting record and final determination after the advisory recommendation
• First-in-human administered-MOTS-c trials with clear identity and route
• Studies that measure clinical outcomes rather than endogenous biomarker changes alone

Sources and records

• FDA staff briefing — MOTS-c-related bulk drug substances (2026)
• von Walden et al., 2021 — exercise and endogenous mitochondrial-derived peptides
• Gudiksen et al., 2026 — muscle bioenergetics and MOTS-c
• FDA meeting page — July 23–24, 2026 PCAC
• FDA voting questions — exact free-base and acetate questions (PDF)
• FDA-linked Day 1 archived broadcast — MOTS-c votes

Educational journalism only; not medical or legal advice. We do not link vendors or publish protocols.